
JNJ
Johnson & Johnson
Pharmaceuticals, medical devices, consumer health products. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
13
$63.69M
Insider Sales
6
$29.19M
Total Volume
$92.88M
42 transactions
Net Activity
+$34.49M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
High Conviction Accumulation
Key Drivers
- •Moderate accumulation: purchases represent 69% of total transaction value.
- •Cluster buying: 5 unique insiders purchased shares, showing strong alignment.
- •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
- •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
- •Ultra-high accumulation: total purchase value exceeds $10M.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Joaquin Duato
CEO
$23.71M total
Joseph Wolk
CFO
$21.73M total
VP Operations
VP
$15.73M total
Chief Operating Officer
COO
$15.65M total
Board Director
Dir
$12.34M total
Quick Actions
JNJ has an insider buy conviction of 69%, compared to the Healthcare sector buy average of 0%. JNJ ranks #1 in insider activity out of 1 tracked companies in its industry.
Over the last 90 days, corporate insiders at Johnson & Johnson (JNJ) engaged in a total of 42 transactions reported via SEC Form 4 filings. Among these, 13 were open-market purchases and 6 were sales. The total volume of insider trading reached $92.88M.
The net insider activity for JNJ shows a net buying bias of $34.49M. This activity represents a 69% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Joaquin Duato (CEO), who traded 46.8K shares valued at $9.67M on Sep 21, 2026.
Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit
Jim Cramer says J&J is a 'metaphor for what's working' in the stock market
Johnson & Johnson's arthritis drug reduced inflammation near the spine more than twice as much as a placebo did.
Guggenheim Names Top Biotech Stock Pick Following JNJ Latest Deal
Stock Screening Made Simple: A Closer Look
Why Is JNJ Stock Beating Rivals That Grow Faster?
Explore Peers in Drug Manufacturers
Compare insider activity and sentiment scores across similar organizations.
FAQs About Johnson & Johnson Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for JNJ.

